Reynolds Consumer Products Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Reynolds Consumer Products Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.76B | Feb 7, 2024 |
| FY2023 | Dec 31, 2022 | $3.82B | Feb 7, 2024 |
| FY2023 | Dec 31, 2021 | $3.56B | Feb 7, 2024 |
| FY2020 | Dec 31, 2020 | $888.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $823.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $822.00M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $730.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $835.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2019 | $741.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2019 | $791.00M | Feb 12, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.72B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.70B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $3.76B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $3.82B | Feb 5, 2025 |
| FY2022 | Dec 31, 2021 | $3.45B | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | $3.15B | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $2.88B | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $2.98B | Feb 12, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $914.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $978.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $942.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $776.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $811.00M | Feb 7, 2024 |
| FY2020 | Dec 31, 2020 | $267.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $265.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $252.00M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $189.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $263.00M | Feb 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $301.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $352.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $298.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $258.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $324.00M | Feb 7, 2024 |
| FY2020 | Dec 31, 2020 | $112.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $113.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $112.00M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $26.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $90.00M | Feb 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $45.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $44.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $38.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $36.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $41.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $33.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $29.00M | Feb 12, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $382.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $429.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $430.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $340.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $320.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $358.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $305.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $288.00M | Feb 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $477.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $489.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $644.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $219.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $310.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $319.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $403.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $530.00M | Feb 12, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $161.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $120.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $104.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $128.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $141.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $143.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $109.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $82.00M | Feb 12, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.94B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.87B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $4.78B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $4.93B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $4.81B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $4.72B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $4.16B | Feb 12, 2021 |
| FY2020 | Dec 31, 2018 | $6.42B | Feb 12, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.68B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $2.73B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $2.80B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $3.06B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $3.06B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $3.11B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $4.98B | Feb 12, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.25B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $2.14B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $1.98B | Feb 4, 2026 |
| FY2025 | Dec 31, 2022 | $1.87B | Feb 4, 2026 |
| FY2024 | Dec 31, 2021 | $1.76B | Feb 5, 2025 |
| FY2023 | Dec 31, 2020 | $1.62B | Feb 7, 2024 |
| FY2022 | Dec 31, 2019 | ($818.00M) | Feb 8, 2023 |
| FY2021 | Dec 31, 2018 | ($1.03B) | Feb 9, 2022 |
| FY2020 | Dec 31, 2017 | ($1.30B) | Feb 12, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $1.90B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $1.90B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $1.88B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $1.88B | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $1.88B | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $1.88B | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $1.88B | Feb 12, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $802.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $694.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $537.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $431.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $365.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $233.00M | Feb 9, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $137.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $115.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $38.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $164.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $312.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $102.00M | Feb 12, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59B | Feb 4, 2026 |
| FY2023 | Dec 31, 2023 | $1.83B | Feb 7, 2024 |
| FY2023 | Dec 31, 2022 | $2.09B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $2.11B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $2.23B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $2.01B | Feb 12, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 7, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 12, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 7, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 12, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 210.30M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 210.30M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | 210.20M | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | 210.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | 210.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | 210.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | 209.70M | Feb 12, 2021 |